Our mission is to detect cancer earlier and to increase survival rates
See our crowdfunding video (Norwegian language)
GreinDX develops ground-breaking liquid biopsy technology to empower clinicians, researchers, and industry in the fight against cancer.
GreinDX has addressed a fundamental challenge in fluid handling by developing a porous silicon disc that enables uniform distribution of fluids and their constituents. Our GreinDisc allows capture and analysis of single viable cells across more than one million microwells, creating new opportunities for simplified and scalable liquid biopsy workflows, as well as broad applications in biology and chemistry.
The Company
GreinDX AS is developing a ground-breaking liquid biopsy platform to rapidly capture, identify and analyse single circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), circulating tumor antigens (CTA) and extracellular vesicles (EV), all from one and the same blood sample. Such timely and accurate multi biomarker information will become a cornerstone for future personalized cancer care.
We are located in Oslo Cancer Cluster Incubator (OCCI) and have a wide international network of scientific and technology resources. We have partnered with clinical R&D groups at Oslo University Hospital and The Karolinska Institute for early-stage validation, and with SINTEF MiNaLab for development of microstructures and fluidic components of our device.
We have partnered with Vinn Group AB in Sweden for prototype development.
GreinDX is developing a first of its kind, proprietary, comprehensive bench-top system that can capture and study single viable CTCs, ctDNA, EVs and CTA from a single blood sample or from other body fluids
The Problem
Scientists have for decades searched for evidence of cancer in a person’s bloodstream. The ability to isolate and study viable CTCs as well as ctDNA, CTA and EV in blood and other body fluids is expected to become a critical factor in future diagnostic, prognostic and personalized therapeutic cancer programs. However, current solutions are single biomarker focused, cumbersome, time consuming and expensive.
Our Solutiuon
GreinDX AS is developing a first of its kind, proprietary, and comprehensive bench-top system that can capture and study viable CTCs, ctDNA, CTA and EVs from a single blood sample or other body fluids. Our platform also holds promise within the rapidly growing organoid field.
Our Technology
GreinDX has solved a fundamental problem in fluid dynamics by developing a porous surface with properties that enable Poisson distribution of a fluid and its constituents. This GreinDisc holds great promises for liquid biopsies and for a wide range of other application areas within both biology and chemistry.
Our novel liquid biopsy platform that will be far more comprehensive, more precise, faster and come at a much lower price than current products.
Liquid Biopsies in Cancer -
a future standard clinical tool
While biopsies of tumors are currently considered the gold standard practice, they are invasive procedures that typically require surgery or needles. Often there’s insufficient tissue to analyze, or a tumor is precariously located, making a biopsy unsafe. Tissue biopsies can detect the presence of cancer, but they are inadequate for early detection, monitoring patients for relapse and/or identifying the need for alternative treatments.
Several single-biomarker liquid biopsy tests has been developed and some are approved for clinical use. The ability to isolate and study circulating tumor cells (CTC) as well as circulating tumor DNA (ctDNA), extracellular vesicles (EVs) and circulating tumor antigens (CTA) in blood and other body fluids is expected to become a critical factor in future diagnostic, prognostic and personalized therapeutic cancer programs
There is a need to fuse capture and analysis of CTCs, ctDNA, exosomes and proteins into one platform.
Circulating tumor DNA (ctDNA) is found in the bloodstream and refers to DNA that is fragmented from the cancerous cells and tumors.
Extracellular vesicles (EVs) are lipid bilayer-delimited particles that are naturally released from almost all types of cell and, unlike a cell, cannot replicate.
Circulating tumor cells (CTC) are cells that have shed into the vasculature or lymphatics from a primary tumor and is carried around the body in the blood circulation.
Circulating tumor antigen (CTA) are multifunctional protein groups with specific expression patterns in normal embryonic and adult cells and various types of cancer cells.
The People
Welcome to our dedicated team at GreinDX. We are a group of passionate entrepreneurs, researchers, and clinicians, all committed to advancing cancer research and patient care. Each of us brings unique expertise and a shared determination to make a difference in the fight against cancer. We work together, driven by compassion and a relentless pursuit of knowledge and technology that can improve outcomes for patients and their families.
The Team
Dr. Amir Lichtenstein
CTO and Co-Founder
Prof. Yossi Weissmann
CSO, Chemistry&Biology
Dagim Tadele, PhD
Post-doc OUH
Ove V. Solesvik
CEO and Co-Founder
Director of the Board
Ehud Hahamy MSc
IT/AI specialist, Consultant
Dr. Micha Feigin-Almon
Senior Scientist, MIT Consultant
The Board of Directors
Ove V. Solesvik
CEO and Co-Founder
Director of the Board
Christian Fredrik Stray
CEO, MedEasy Group
Board Member
Prof. Ole Petter Ottersen
Former President, Karolinska Institute
Board Member
Dr. Amir Lichtenstein
Co-Founder
Board Member
The Advisory Board
Prof. Vessela Kristensen
Head of Research and Development Department of Medical Genetics
Oslo University Hospital
Prof. Bjørn Tore Gjertsen
Center for Cancer biomarkers
Haukeland University Hospital
Prof. Eivind Hovig
Leader of the Centre for Bioinformatics
University of Oslo
Dr. Michal Mielnik
SINTEF MiNaLab
SINTEF
Other advisors
Dr. Darren Ellis
Bus development, Consultant
Mr. Morten Jurs
ex SpinChip/BioMerieux
For both preventive and precision medicine, we are seeing increasing interest in the use of liquid biopsies in the oncology space. However, there is, to our knowledge, no system currently available that allows identification, capture, isolation, and cultivating of circulating tumor cells (CTC) and other key cancer biomarkers in a single product. We are intrigued by the comprehensive approach that GreinDX is taking to address this challenge and are enthusiastic about the prospect of this “all in one” solution.
Mark J. Powers, Ph.D
Vice President R&D – Cell Systems
Our Partners
SINTEF MiNaLab
Sintef MiNaLab has a complete Si processing line for 150mm wafers with state-of-the-art production equipment. The lab is ISO 9001-2015, ISO 14001-2015 and OHSAS 18001:2007 certified and belongs to the SINTEF ICT department Microsystems and Nanotechnology. Both Norwegian and international industry uses SINTEF MiNaLab for production of key components.
Dr. Michal Mielnik
SINTEF MiNaLab
The European Liquid Biopsy Society (ELBS)
The ELBS pursues a holistic approach to tackling the challenges of clinical implementation in the liquid biopsy field. The network incorporates key players from academia, clinic, industry, and national government agencies to move this promising field forward collectively. Currently the focus of the ELBS is cancer; however, we are open to including additional liquid biopsy research fields in the future (e.g. cardiovascular or inflammatory diseases).
The ELBS represents a precompetitive arena for industry partners to test and refine their technologies, assays and pipelines through the feedback of top researchers in the field.
Vinn Group AB
Vinn is a platform for starting up new, innovative service providers. We’re currently made up of a group of specialist companies and individuals with high-calibre expertise assembled in a creative environment. Through faster, better development, Vinn seeks to work alongside companies’ employees and customers to achieve success, and in the long-term, create a better world.
Hans Johansson
Vinn Group AB
Oslo University Hospital
Prof. Vessela Kristensen`s group is working on different projects related to how genetic variation affects occurrence of somatic alterations, gene expression patterns and genome wide copy number alterations in human breast and ovarian tumors. Understanding inherited genetic variability and how it affects crucial biological pathways is likely to lead to new successful prevention and treatment strategies.
Prof. Vessela Kristensen
Oslo University Hospital
The Karolinska Institute
Intro to Petter Woll’s group studies cellular and molecular mechanisms promoting establishment and propagation of leukemic stem cells. We wish to understand the cellular and molecular targets for highly recurrent mutations in hematologic malignancies, in order to prevent leukemia and treat the patient.
Prof. Petter Woll
The Karolinska Institute
We want to hear from you!
Our development of a new diagnostic platform will be both demanding and challenging, but we are driven and fueled by our team’s expertise, curiosity and optimism. As Einstein once said,“Concern for man and his fate must always form the chief interest of all technical endeavors.” We hope you join us on our journey of making early detection of cancer available for everyone.